about
Proteomic Investigations into Hemodialysis TherapyDysfunctional High-Density Lipoprotein: An Innovative Target for Proteomics and LipidomicsImmune dysfunction in uremia—an updateResidual Cardiovascular Risk in Chronic Kidney Disease: Role of High-density LipoproteinHDL as a prognostic biomarker for coronary atherosclerosis: the role of inflammation.Genetic variants in CETP increase risk of intracerebral hemorrhage.The atherogenic index of plasma and the risk of mortality in incident dialysis patients: Results from a nationwide prospective cohort in Korea.The Therapeutic Potential of Anti-Inflammatory Exerkines in the Treatment of AtherosclerosisElevated high-density lipoprotein cholesterol and cardiovascular mortality in maintenance hemodialysis patients.HDL in children with CKD promotes endothelial dysfunction and an abnormal vascular phenotypeDysfunctional high-density lipoproteins in children with chronic kidney diseaseAging affects high-density lipoprotein composition and function.Quantification of HDL proteins, cardiac events, and mortality in patients with type 2 diabetes on hemodialysis.Restoration of renal function does not correct impairment of uremic HDL propertiesImpaired High-Density Lipoprotein Anti-Oxidant Function Predicts Poor Outcome in Critically Ill PatientsDialysis Modalities and HDL Composition and FunctionTLR4 mutant mice are protected from renal fibrosis and chronic kidney disease progressionA Cluster of Proteins Implicated in Kidney Disease Is Increased in High-Density Lipoprotein Isolated from Hemodialysis Subjects.Cholesterol Metabolism in CKDBlood volume-monitored regulation of ultrafiltration in fluid-overloaded hemodialysis patients: study protocol for a randomized controlled trial.Psoriasis alters HDL composition and cholesterol efflux capacityAntipsoriatic treatment extends beyond the skin: recovering of high-density lipoprotein functionRole of HDL dysfunction in end-stage renal disease: a double-edged sword.Subfractions of high-density lipoprotein (HDL) and dysfunctional HDL in chronic kidney disease patients.Proteomic diversity of high density lipoproteins: our emerging understanding of its importance in lipid transport and beyondRefined purification strategy for reliable proteomic profiling of HDL2/3: Impact on proteomic complexity.HDL cholesterol is not associated with lower mortality in patients with kidney dysfunction.The effects of colestilan versus placebo and sevelamer in patients with CKD 5D and hyperphosphataemia: a 1-year prospective randomized study.Assessing the functional properties of high-density lipoproteins: an emerging concept in cardiovascular research.Chronic kidney disease induced dysfunction of high density lipoprotein.Beyond tissue injury-damage-associated molecular patterns, toll-like receptors, and inflammasomes also drive regeneration and fibrosis.The vulnerable patient with chronic kidney disease.The role of high-density lipoproteins in the regulation of angiogenesis.Intercellular communication lessons in heart failure.HDL abnormalities in nephrotic syndrome and chronic kidney disease.Kidney function is associated with an altered protein composition of high-density lipoprotein.HDL cholesterol: reappraisal of its clinical relevance.Association of Serum Triglyceride to HDL Cholesterol Ratio with All-Cause and Cardiovascular Mortality in Incident Hemodialysis Patients.Disorders of lipid metabolism in nephrotic syndrome: mechanisms and consequences.HDL Cholesterol Efflux Does Not Predict Cardiovascular Risk in Hemodialysis Patients.
P2860
Q26774276-FEEDA87B-4F24-45AD-8D3D-E0D3457C38D7Q26774903-2E3B8C35-E95D-4C19-B7D9-55956DAE813CQ26829076-84B774AC-6717-4505-BF69-AF56A39EA6E6Q28083619-54705AE0-AF1F-4748-81C4-73B210E95CE3Q30251918-3DF438C0-F2F9-44A5-8976-8FED66326F8CQ30275688-6A8787EF-7B5E-4FD3-A265-AF3899EFCF07Q33732285-EE188840-2079-4512-90FD-C237C277FAA4Q33838927-3C2C5FE6-8168-4C61-BC9F-3ABB2DA6F1C1Q33932598-CD1535BD-2918-445B-9611-B498DAC5C0B8Q34427695-A144DE8C-CAE7-46A2-915C-11AA8726D912Q34779002-C966ACB8-A7A1-44A9-9152-9A890F4AA3B8Q34781392-C5BE2608-7C3A-4A1E-B2B6-F82F5F8D3A96Q35051225-7AFE2308-7D6E-463A-AC59-68FB27BC8831Q35124223-5258973A-33B3-4F52-9365-295841582AF3Q35957788-D42B2487-B234-4DED-9530-032A250E439CQ36003077-FF6544D9-8142-4C4C-93BA-CEBE5568FDF2Q36144601-5DD4956A-4F37-4139-8021-F89C42617F6CQ36257138-4560A381-8D3D-471D-A1E6-6C74FE980D71Q36315574-F140ADD7-2DC7-4ECA-9D62-4271360784C7Q36383953-014CB149-96A8-4ACF-AD68-8104E4D2AADFQ36520321-44327C00-9C10-477C-97FC-9013F2E08646Q36681220-032BAD93-815F-4F0F-BB69-AD9C88A27E00Q36876162-8F60D75B-443F-4775-9765-BFD1242A13FBQ37100557-0BF2AFBB-94EE-4807-8E47-4B723E6147ACQ37162996-3B965A7E-DD4C-4FEF-9151-B1799710E95EQ37472192-7A4B39B4-FD18-4A28-AD4C-C2FBA776C3DFQ37733566-B68D9EBF-F95A-40BD-8879-1B5EB54C4370Q37734160-4FB51EF2-3ACB-42B3-9B6C-FAD7B1FCA0A2Q38111810-9DDBF4C9-8F49-4A55-8015-2BD299E73DDBQ38135683-C28A40EB-D1AD-438F-A9C3-452C88F97DB8Q38206875-19C53F0E-D52A-4063-B134-0A78565AE8CBQ38368207-BA7B671F-9CCB-481D-B8C7-5B7896A2676CQ38373133-CB87315C-34AB-4175-975B-71D667C8404BQ38591546-B3319E62-E8EB-4F44-9EBD-3B39DC7AA1C1Q38633497-6DF9566C-60BA-43C9-AB0D-A2EA9BD9DF02Q38650168-DD522DA6-5D7F-4344-8FD5-B1221BD03DFEQ38739884-E6B6690A-1F28-4269-811A-F9A75069100AQ38758014-A0E1639B-9176-4183-B38C-0304AC50FAE5Q38831462-41F00398-2C32-4BFF-AA33-BAD86CB00808Q40587729-F03C2483-E2CA-4E4B-970D-3EEAED91ACAB
P2860
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Serum amyloid A in uremic HDL promotes inflammation
@ast
Serum amyloid A in uremic HDL promotes inflammation
@en
type
label
Serum amyloid A in uremic HDL promotes inflammation
@ast
Serum amyloid A in uremic HDL promotes inflammation
@en
prefLabel
Serum amyloid A in uremic HDL promotes inflammation
@ast
Serum amyloid A in uremic HDL promotes inflammation
@en
P2093
P2860
P356
P1476
Serum amyloid A in uremic HDL promotes inflammation
@en
P2093
Cacang Suarna
Chantal Kopecky
Dominik Döller
Gerhard J Zlabinger
Karl Katholnig
Marcus D Säemann
Markus Kubicek
Markus Tölle
Markus van der Giet
Michael Haidinger
P2860
P304
P356
10.1681/ASN.2011070668
P577
2012-01-26T00:00:00Z